DOCSLIB.ORG

FRI SUN AB 3.15Pm 2019 NCODA Fall Oral Oncology Upate

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

NEW OPTIONS FOR PATIENTS: 2019 ORAL ONCOLOGY UPDATE Kirollos Hanna, PharmD, BCPS, BCOP Assistant Professor of Pharmacy Mayo Clinic College of Medicine Hematology/Oncology Clinical Pharmacist M Health Fairview FACULTY DISCLOSURES Kirollos S. Hanna, PharmD, BCPS, BCOP has the following disclosures with commercial interests to disclose: Consultant – Seattle Genetics, Hyloris Pharmaceuticals; Speaker's Bureau - Seattle Genetics, Abbvie; Stock/ Shareholder – CVS; Advisory Boards - Aztrazeneca, Incyte, Sandoz, Rigel, Taiho, Heron, Astellas, Seattle Genetics, Abbvie The content of this activity may include information regarding the use of products that may be inconsistent with, or outside the approved labeling for, these products in the United States. Pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult the prescribing information for these products. DRUG APPROVALS AND EXPANSION 2018 – 2019 • 2018 – 63 Oral updates • 2018 – 27 2019 – 8 novel • 2019 – 33 updates therapies updates • 2019 – 18 Overall updates Novel Hematology/Oncology (Cancer) Approvals & Safety Notifications. FDA; FDA website. Accessed October 19, 2019. THE ROLE OF HCPS IN OC MANAGEMENT Maintenance •AE management •Adherence and Need for Coordination compliance •Cyclic labs •Cyclic labs •Methods of •Refills Medically Initiation communication •Drug-drug interactions •Refills Integrated •Inappropriate dosing •Provider appointments •Baseline labs and •Updated insurance plans monitoring Model •Need for education •Insurance and procurement Pharmacists provide clinical considerations and operational best practices to optimize oral chemotherapy dispensing and management. Timmers L, et al. BMC Cancer. 2017;17(1):122; Mulkerin DL, et al. J Oncol Pract. 2016;12(10):e912-e923; Battis B, et al. J Oncol Pharm Pract. 2017;23(8):582-590. TIMELINE SINCE SPRING FORUM: NOVEL AGENTS Apr 12: Erdafitnib - Bladder Apr 19: PemAxi - Renal May 2: Ivosidenib - AML May 14: AvelAxi - Renal May 15: Venetoclax - CLL May 24: Ruxolitinib - aGVHD May 24: Alpelisib - Breast May 28: LenR – FL and MZL May 29: Gilteritinib - OS for AML July 3: Selinexor – MM July 30: Darolutamide - Prostate Aug 2: Pexidartinib – TGCT Aug 15: Entrectinib – NTRK/ROS Aug 16: Fedratinib – MF Aug 15: PemLen – Endometrial Sep 17: Apalutamide – Prostate Hematology/Oncology (Cancer) Approvals & Safety Notifications. FDA; FDA website. Accessed October 19, 2019. TIMELINE SINCE SPRING FORUM: COMBINATIONS Apr 12: Erdafitnib - Bladder Apr 19: PemAxi - Renal May 2: Ivosidenib - AML May 14: AvelAxi - Renal May 15: Venetoclax - CLL May 24: Ruxolitinib - aGVHD May 24: Alpelisib - Breast May 28: LenR – FL and MZL May 29: Gilteritinib - OS for AML July 3: Selinexor – MM July 30: Darolutamide - Prostate Aug 2: Pexidartinib – TGCT Aug 15: Entrectinib – NTRK/ROS Aug 16: Fedratinib – MF Aug 15: PemLen – Endometrial Sep 17: Apalutamide – Prostate Hematology/Oncology (Cancer) Approvals & Safety Notifications. FDA; FDA website. Accessed October 19, 2019. NOVEL ORAL THERAPIES UROTHELIAL CARCINOMA: ERDAFITINIB • Indication: locally advanced or mUC FGFR3/FGFR2 alterations, following platinum-containing chemotherapy • BLC2001 Study: open-label, phase 2 Endpoint ITT Efficacy (n=87) Endpoint FGFR Efficacy (n=64) FGFR3 Point Mutation ORR (95% CI) 32.2% (22.4, 42.0) (n=64) 40.6% (28.6, 52.7) ORR (95% CI) CR 2.3% FGFR3 Fusion (n=18) 11.1% (0, 25.6) PR 29.9% ORR (95% CI) FGFR2 Fusion (n=6) 0 Median DoR 5.4 (4.2, 6.9) ORR (95% CI) Loriot Y, Necchi A, Park SH, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019;381(4):338-348. ERDAFITINIB PEARLS All Grade Grade 3-4 Adverse Reaction (8 mg/day) (%) (%) Any 100 67 • Novel mechanism of action, 1st targeted therapy and orally Gastrointestinal disorders 92 24 Metabolism and nutrition available option in UC treatment 90 16 • MOA: Pan-FGFR inhibitor (FGFR 1-4) disorders General disorders and admin. • Approved for FGFR 2-3 mutations or 69 13 fusions site conditions Skin and subcutaneous • 8 mg PO daily (w/ or w/o food) 75 16 with dose increase to 9 mg daily if disorders criteria are met Eye disorders 62 11 • Day 14 to 21 phosphorus < 5.5 mg/dL Nervous system disorders 57 5 • No ocular disorders Infections and infestations 56 20 • No grade ≥ 2 AEs Respiratory, thoracic, and 40 7 • Increase occurred in 41% of pts mediastinal disorders • Restricted distribution (US Renal and urinary tract disorders 38 10 Bioservices specialty pharmacy): Musculoskeletal and connective 31 0 Tablets: 3 mg, 4 mg, 5 mg tissue disorders Balversa (erdafitinib) [prescribing information]. Horsham, PA: Janssen Products; April 2019. ERDAFITINIB OCULAR TOXICITY • Central serous retinopathy/retinal pigment epithelial detachment (CSR/RPED) were reported in 25% of patients • First onset of 50 days • Grade 3 in 3% of patients • Usually resolve or improve after dose hold • Ongoing in 13% of patients at the study cutoff • 9% dose interruptions, 14% reductions, 3% discontinuations • Dry eye symptoms occurred in 28% of patients with grade 3 in 6% of patients • All patients should receive dry eye prophylaxis with ocular demulcents as needed • Monthly ophthalmological examinations during the first 4 months of treatment and every 3 months afterward, and urgently at any time for visual symptoms • Assessment of visual acuity, slit lamp examination, fundoscopy, optical coherence tomography Balversa (erdafitinib) [prescribing information]. Horsham, PA: Janssen Products; April 2019. AML: IVOSIDENIB • Indication: newly-diagnosed AML with IDH1 mutation in patients ≥ 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy • AG120-C-001 Study: open-label, single-arm, phase 1 Endpoint ITT Efficacy (n=125) r/r AML Efficacy ORR 41.6% 39.1% CR 21.6% 21.8% CRh 12.8% 11.7% Median time to CR/Cri 2.7 months 2.0 months Median duration of CR/Cri 8.2 months 6.5 months Median time to response 1.9 months 1.9 months Dinardo CD, Stein EM, De botton S, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018;378(25):2386-2398. IVOSIDENIB PEARLS trAEs of Grade ≥ 3 in > 1% of the Overall • IDH1 Inhibitor Population. ITT r/r AML Event Population (n=179) • 500 mg daily; avoid high fat (n=258) meals ≥ trAE 20.7% 25.6% Prolonged QTc 7.8% 7% • Warnings: QT prolongation, Differentiation Syndrome 3.9% 4.7% Guillain-Barre’ Syndrome, DS Anemia 2.2% 2.3% Thrombocytopenia 1.7% 1.9% • Drug Interactions: CYP 3A4 Leukocytosis 1.7% 1.2% Inducers and Inhibitors; avoid QT prolonging drugs and 3A4 Febrile Neutropenia 0.6% 1.2% substrates Diarrhea 0.6% 1.2% Hypoxia 1.1% 1.2% Dinardo CD, Stein EM, De botton S, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018;378(25):2386-2398. MULTIPLE MYELOMA: SELINEXOR • Indication: r/r MM after ≥ 4 prior therapies (2 PIs, 2 IMiDs, and anti-CD38 monoclonal antibody) • Storm Trial: phase 2b, single-arm, open-label, multicenter Endpoint ITT Efficacy (n=87) ORR (95% CI) 25.3% (16.4, 36) Stringent Complete Response (sCR) 1% Complete Response (CR) 0 Very Good Partial Response (VGPR) 5% Partial Response (PR) 19% Xpovio (selinexor) [prescribing information]. Newton, MA: Karyopharm Therapeutics Inc; July 2019. SELINEXOR PEARLS Any • 80 mg in combination with Grade ≥ 3 Select Event Grade (n=202) dexamethasone taken orally on (n=202) Days 1 and 3 of each week Thrombocytopenia 74% 61% Fatigue 73% 22% • 5-HT3 antagonist and/or other Nausea 72% 9% anti-nausea agents prior to and Anemia 59% 40% during treatment Weight decrease 47% 0.5% First Second Third Diarrhea 44% 6% Reduction Reduction Reduction Hyponatremia 39% 22% 100 mg 80 mg 60 mg D/C Neutropenia 34% 21% once once once weekly weekly weekly Constipation 25% 1.5% Xpovio (selinexor) [prescribing information]. Newton, MA: Karyopharm Therapeutics Inc; July 2019. SELINEXOR MOA Adapted from Karyopharm, Selinexor Mechanism of Actions. https://www.xpovio.com/hcp/. Accessed October 19, 2019. PROSTATE: DAROLUTAMIDE • Indication: non-metastatic castration-resistant prostate cancer • ARAMIS Study: phase 3, multicenter, double-blind, placebo-controlled Darolutamide Efficacy Placebo Efficacy Endpoint (n=955) (n=554) Metastasis-free survival Number of Events 23% 39% Median, months (95% CI) 40.4 (34.3, NR) 18.4 (15.5, 22.3) Hazard Ratio (95% CI) 0.41 (0.34, 0.50) P-value <0.0001 Fizazi K, Shore N, Tammela TL, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2019;380(13):1235-1246. DAROLUTAMIDE PEARLS • 300mg BID w/ food • Gonadotropin-releasing hormone (GnRH) analog required Placebo Efficacy Darolutamide Efficacy (n=954) Event (n=554) All Grade Grade ≥ 3 All Grade Grade ≥ 3 Fatigue 16% 0.6% 11% 1.1% Pain in extremity 6% 0 3% 0.2% Anemia 3% 0.1% 1% 0 Fizazi K, Shore N, Tammela TL, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2019;380(13):1235-1246. TENOSYNOVIAL GIANT CELL TUMOR: PEXIDARTINIB • Indication: symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery • ENLIVEN study: phase 3, international, multicenter, randomized Pexidartinib Efficacy Placebo Efficacy Endpoint (n=61) (n=59) ORR (95% CI) 38% (27, 50) 0 (0, 6) CR 15% 0 PR 23% 0 P-value <0.0001 DoR 6.9+, 24.9+ NA Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019. PEXIDARTINIB PEARLS • First systemic therapy for TGCT Pexidartinib Placebo (n=61) (n=59) Any Grade Any Grade • 400 mg BID w/o food Select Event Grade ≥ 3 Grade ≥ 3 • Dose reduce with strong 3A4 or UGT Hair Color Changes 67% 0 3.4% 0 inhibitors Rash 28% 1.6% 7% 0 Pruritus 18% 0 3.4% 0 • Avoid PPIs Fatigue 64% 0 41% 0 Peripheral Edema 20% 0 7% 0 Total Daily Modified Third Eye Edema 30% 1.6% 5% 0 Dose Daily Dose Reduction Dysgeusia 26% 0 1.7% 0 800 mg 400 mg 200 mg BID Neuropathy 10% 0 5% 0 600 mg 400 mg 200 mg BID Vomiting 20% 1.6% 5% 0 400 mg 200 mg 200 mg QD Hypertension 15% 4.9% 10% 0 Tap WD, Gelderblom H, Palmerini E, et al.
Recommended publications
  • Stanford Chem-H Presentation (PDF)

    Stanford Chem-H Presentation (PDF)

    KiNativ® In situ kinase profiling Stanford University ChEM-H confidential @KiNativPlatform Principle of the KiNativ platform • ATP (or ADP) acyl phosphate binds to, and covalently modifies Lysine residues in the active site • Thus, ATP acyl phosphate with a desthiobiotin tag can be used capture and quantitate kinases in a complex lysate Acyl phosphate Desthiobiotin tag ATP 2 ATP acyl phosphate probe covalently modifies kinase in the active site Lysine 2 Lysine 1 3 ATP acyl phosphate probe covalently modifies kinase in the active site Lysine 2 Lysine 1 4 Samples trypsinized, probe-labeled peptides captured with streptavidin, and analyzed by targeted LC-MS2 Identification Quantitation Explicit determination of peptide Integration of signal from MS2 sequence and probe modification site fragment ions from MS2 spectrum 5 Comprehensive Coverage of Protein and Lipid Kinases Protein kinases Atypical kinases Green: Kinases detected on KiNativ Red: Kinases not detected on KiNativ ~80% of known protein and atypical kinases identified on the platform http://www.kinativ.com/coverage/protein-lipid.html 6 Profiling compound(s) on the KiNativ platform Control sample – add probe Sample: Lysate derived from any cell line or tissue from ANY species Treated sample – add inhibitor followed by probe Inhibited kinase Green: Kinases Blue: Probe Gray: Non-kinases Red: Inhibitor 7 Profiling compound(s) on the KiNativ platform Control sample – add probe MS signalMS Sample: Lysate derived from any cell line or tissue from ANY species Treated sample – add inhibitor
  • Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia

    Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia

    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2019 Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia La Starza, Roberta ; Cambò, Benedetta ; Pierini, Antonio ; Bornhauser, Beat ; Montanaro, Anna ; Bourquin, Jean-Pierre ; Mecucci, Cristina ; Roti, Giovanni DOI: https://doi.org/10.1200/PO.19.00172 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-198023 Journal Article Published Version The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License. Originally published at: La Starza, Roberta; Cambò, Benedetta; Pierini, Antonio; Bornhauser, Beat; Montanaro, Anna; Bourquin, Jean-Pierre; Mecucci, Cristina; Roti, Giovanni (2019). Venetoclax and Bortezomib in Relapsed/Refrac- tory Early T-Cell Precursor Acute Lymphoblastic Leukemia. JCO precision oncology, 3:PO.19.00172. DOI: https://doi.org/10.1200/PO.19.00172 case report Venetoclax and Bortezomib in Relapsed/ Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia Roberta La Starza, MD, PhD1; Benedetta Cambo,` MD2; Antonio Pierini, MD, PhD1; Beat Bornhauser, PhD3; Anna Montanaro2; Jean-Pierre Bourquin, MD, PhD3; Cristina Mecucci, MD, PhD1; and Giovanni Roti, MD, PhD2 INTRODUCTION CD2, CD4, CD8, and CD1a and positive for human Although in the past three decades we welcomed the leukocyte antigen (HLA-DR), CD38, CD117, CD33, advent of targeted therapies in
  • A Phase I Study of Pexidartinib, a Colony-Stimulating Factor 1 Receptor Inhibitor, in Asian Patients with Advanced Solid Tumors

    A Phase I Study of Pexidartinib, a Colony-Stimulating Factor 1 Receptor Inhibitor, in Asian Patients with Advanced Solid Tumors

    Investigational New Drugs https://doi.org/10.1007/s10637-019-00745-z PHASE I STUDIES A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors Jih-Hsiang Lee1 & Tom Wei-Wu Chen2 & Chih-Hung Hsu2,3 & Yu-Hsin Yen2 & James Chih-Hsin Yang2,3 & Ann-Lii Cheng2,3 & Shun-ichi Sasaki4 & LiYin (Lillian) Chiu5 & Masahiro Sugihara4 & Tomoko Ishizuka4 & Toshihiro Oguma4 & Naoyuki Tajima4 & Chia-Chi Lin2,6 Received: 15 January 2019 /Accepted: 7 February 2019 # The Author(s) 2019 Summary Background Pexidartinib, a novel, orally administered small-molecule tyrosine kinase inhibitor, has strong selectivity against colony- stimulating factor 1 receptor. This phase I, nonrandomized, open-label multiple-dose study evaluated pexidartinib safety and efficacy in Asian patients with symptomatic, advanced solid tumors. Materials and Methods Patients received pexidartinib: cohort 1, 600 mg/d; cohort 2, 1000 mg/d for 2 weeks, then 800 mg/d. Primary objectives assessed pexidartinib safety and tolerability, and determined the recommended phase 2 dose; secondary objectives evaluated efficacy and pharmacokinetic profile. Results All11patients(6males,5 females; median age 64, range 23–82; cohort 1 n = 3; cohort 2 n = 8) experienced at least one treatment-emergent adverse event; 5 experienced at least one grade ≥ 3 adverse event, most commonly (18%) for each of the following: increased aspartate aminotransfer- ase, blood alkaline phosphatase, gamma-glutamyl transferase, and anemia. Recommended phase 2 dose was 1000 mg/d for 2 weeks and800mg/dthereafter.Pexidartinibexposure,areaundertheplasmaconcentration-timecurvefromzeroto8h(AUC0-8h), and maximum observed plasma concentration (Cmax) increased on days 1 and 15 with increasing pexidartinib doses, and time at Cmax (Tmax) was consistent throughout all doses.
  • Press Release

    Press Release

    Press Release Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo’s HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201) Collaboration combines Daiichi Sankyo’s scientific and technological excellence with AstraZeneca’s global experience and resources in oncology to accelerate and expand the potential of [fam-] trastuzumab deruxtecan as monotherapy and combination therapy across a spectrum of HER2 expressing cancers AstraZeneca to pay Daiichi Sankyo up to $6.90 billion in total consideration, including $1.35 billion upfront payment and up to an additional $5.55 billion contingent upon achievement of future regulatory and sales milestones as well as other contingencies Companies to share equally development and commercialization costs as well as profits worldwide from [fam-] trastuzumab deruxtecan with Daiichi Sankyo maintaining exclusive rights in Japan Daiichi Sankyo is expected to book sales in U.S., certain countries in Europe, and certain other markets where Daiichi Sankyo has affiliates; AstraZeneca is expected to book sales in all other markets worldwide, including China, Australia, Canada and Russia Tokyo, Munich and Basking Ridge, NJ – (March 28, 2019) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it has entered into a global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s lead antibody drug conjugate (ADC), [fam-] trastuzumab deruxtecan (DS-8201), currently in pivotal development for multiple HER2 expressing cancers including breast and gastric cancer, and additional development in non-small cell lung and colorectal cancer. Daiichi Sankyo and AstraZeneca will jointly develop and commercialize [fam-] trastuzumab deruxtecan as a monotherapy or a combination therapy worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights.
  • Identification of Candidate Repurposable Drugs to Combat COVID-19 Using a Signature-Based Approach

    Identification of Candidate Repurposable Drugs to Combat COVID-19 Using a Signature-Based Approach

    www.nature.com/scientificreports OPEN Identifcation of candidate repurposable drugs to combat COVID‑19 using a signature‑based approach Sinead M. O’Donovan1,10, Ali Imami1,10, Hunter Eby1, Nicholas D. Henkel1, Justin Fortune Creeden1, Sophie Asah1, Xiaolu Zhang1, Xiaojun Wu1, Rawan Alnafsah1, R. Travis Taylor2, James Reigle3,4, Alexander Thorman6, Behrouz Shamsaei4, Jarek Meller4,5,6,7,8 & Robert E. McCullumsmith1,9* The COVID‑19 pandemic caused by the novel SARS‑CoV‑2 is more contagious than other coronaviruses and has higher rates of mortality than infuenza. Identifcation of efective therapeutics is a crucial tool to treat those infected with SARS‑CoV‑2 and limit the spread of this novel disease globally. We deployed a bioinformatics workfow to identify candidate drugs for the treatment of COVID‑19. Using an “omics” repository, the Library of Integrated Network‑Based Cellular Signatures (LINCS), we simultaneously probed transcriptomic signatures of putative COVID‑19 drugs and publicly available SARS‑CoV‑2 infected cell lines to identify novel therapeutics. We identifed a shortlist of 20 candidate drugs: 8 are already under trial for the treatment of COVID‑19, the remaining 12 have antiviral properties and 6 have antiviral efcacy against coronaviruses specifcally, in vitro. All candidate drugs are either FDA approved or are under investigation. Our candidate drug fndings are discordant with (i.e., reverse) SARS‑CoV‑2 transcriptome signatures generated in vitro, and a subset are also identifed in transcriptome signatures generated from COVID‑19 patient samples, like the MEK inhibitor selumetinib. Overall, our fndings provide additional support for drugs that are already being explored as therapeutic agents for the treatment of COVID‑19 and identify promising novel targets that are worthy of further investigation.
  • Daiichi Sankyo Group Value Report 2019

    Daiichi Sankyo Group Value Report 2019

    External Evaluations (as of June 30,2019) ™ Daiichi Sankyo Group Value Report 2019 Value Daiichi Sankyo Group MSCI Japan Empowering Women Select Index THE INCLUSION OF DAIICHI SANKYO CO.,LTD. IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF DAIICHI SANKYO CO.,LTD. BY MSCI OR ANY OF ITS AFFILIATES. THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADE- MARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES. “Eruboshi” Certification Mark “Kurumin” Certification Mark Logo given to Certified Health and Productivity Management Organization (White500) This report uses FSC® certified paper, which indicates that the paper used to print this Paper report was produced from properly managed forests. 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426, Japan This report was printed using 100% Inks biodegradable printing inks from vegetable Corporate Communications Department oil. Daiichi Sankyo Group Tel: +81-3-6225-1126 CSR Department The waterless printing method used for this Value Report 2019 Tel: +81-3-6225-1067 Printing report minimized the use and release of harmful liquid wastes. https://www.daiichisankyo.com/ Printed in Japan 005_7045687911909.indd 1 2019/09/27 18:22:19 Introduction Our Mission The Core Values and Commitments serve as the criteria for business activities and In addition, we have established the DAIICHI SANKYO Group Corporate Conduct Charter . decision-making used by executive officers and employees in working to fulfill Our Mission . This charter calls on us to fulfill our social responsibilities by acting with the highest ethical Our Corporate Slogan succinctly explains the spirit of Our Mission, Core Values and standards and a good social conscience appropriate for a company engaged in business Commitments.
  • The Tumor Microenvironment and Overcoming Immune Escape Arsen Osipov1, May Tun Saung1, Lei Zheng1 and Adrian G

    The Tumor Microenvironment and Overcoming Immune Escape Arsen Osipov1, May Tun Saung1, Lei Zheng1 and Adrian G

    Osipov et al. Journal for ImmunoTherapy of Cancer (2019) 7:224 https://doi.org/10.1186/s40425-019-0667-0 REVIEW Open Access Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape Arsen Osipov1, May Tun Saung1, Lei Zheng1 and Adrian G. Murphy1,2* Abstract Immunotherapy has led to a paradigm shift in the treatment of many advanced malignancies. Despite the success in treatment of tumors like non-small cell lung cancer (NSCLC) and melanoma, checkpoint inhibition-based immunotherapy has limitations. Many tumors, such as pancreatic cancer, are less responsive to checkpoint inhibitors, where patients tend to have a limited duration of benefit and where clinical responses are more robust in patients who are positive for predictive biomarkers. One of the critical factors that influence the efficacy of immunotherapy is the tumor microenvironment (TME), which contains a heterogeneous composition of immunosuppressive cells. Myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) alter the immune landscape of the TME and serve as facilitators of tumor proliferation, metastatic growth and immunotherapy resistance. Small molecule inhibitors that target these components of the TME have been developed. This special issue review focuses on two promising classes of immunomodulatory small molecule inhibitors: colony stimulating factor-1 receptor (CSF-1R) and focal adhesion kinase (FAK). Small molecule inhibitors of CSF-1R reprogram the TME and TAMs, and lead to enhanced T-cell-mediated tumor eradication. FAK small molecule inhibitors decrease the infiltration MDSCs, TAMs and regulatory T-cells. Additionally, FAK inhibitors are implicated as modulators of stromal density and cancer stem cells, leading to a TME more conducive to an anti-tumor immune response.
  • Cstone Pharmaceuticals 基石藥業

    Cstone Pharmaceuticals 基石藥業

    Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors and/or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development. CStone Pharmaceuticals 基 石 藥 業 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 2616) VOLUNTARY ANNOUNCEMENT CSTONE SUCCESSFULLY HOSTED THE FIRST U.S. R&D DAY IN NEW YORK CStone Pharmaceuticals (the “Company” or “CStone”) announces that it successfully hosted its 2020 U.S. R&D Day in New York City, the United States on January 21, 2020.
  • Tanibirumab (CUI C3490677) Add to Cart

    Tanibirumab (CUI C3490677) Add to Cart

    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
  • ESMO 2019 Update

    ESMO 2019 Update

    ESMO 2019 Update Axel Grothey Director, GI Oncology Research West Cancer Center Research Institute Encorafenib plus Cetuximab With or Without Binimetinib for BRAF V600E–Mutant Metastatic Colorectal Cancer: Expanded Results from a Randomized, 3-Arm, Phase 3 Study vs. the Choice of Either Irinotecan or FOLFIRI plus Cetuximab (BEACON CRC) Josep Tabernero, Axel Grothey, Eric Van Cutsem, Rona Yaeger, Harpreet Wasan, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik-Tobias Arkenau, Pilar Garcia-Alfonso, Ashwin Gollerkeri, Michael Pickard, Kati Maharry, Janna Christy-Bittel, Lisa Anderson, and Scott Kopetz BEACON CRC: Binimetinib, Encorafenib, And Cetuximab COmbiNed to Treat BRAF-mutant ColoRectal Cancer 2 Study Design Patients with BRAFV600E mCRC with disease progression after 1 or 2 prior regimens; ECOG PS of 0 or 1; and no prior treatment with any RAF inhibitor, MEK inhibitor, or EGFR inhibitor Phase 3 Primary Endpoints: Safety Lead-in ENCORAFENIB + Triplet therapy BINIMETINIB + ENCORAFENIB + BINIMETINIB + CETUXIMAB Triplet vs Control n = 205 CETUXIMAB N = 30 OS R Doublet therapy (All randomized Pts) Encorafenib 300 mg PO daily 1:1:1 ENCORAFENIB + CETUXIMAB Binimetinib 45 mg PO bid n = 205 Cetuximab standard weekly ORR – dosing Blinded Central Control arm Review FOLFIRI + CETUXIMAB, or (1st 331 randomized Pts) irinotecan + CETUXIMAB n = 205 Randomization was stratified by ECOG PS (0 vs. 1), prior use of irinotecan (yes vs. no), and cetuximab source (US-licensed vs. EU-approved) Secondary Endpoints: Doublet vs Control and Triplet vs Doublet - OS & ORR, PFS, Safety QOL Assessments: EORTC QOL Questionnaire (QLQ C30), Functional Assessment of Cancer Therapy Colon Cancer, EuroQol 5D5L, and Patient Global Impression of Change).
  • BCBSVT Specialty Drug List Effective 2021.07.01.Xlsx

    BCBSVT Specialty Drug List Effective 2021.07.01.Xlsx

    Effective Date: 07/01/2021 SPECIALTY DRUG LIST Revised Date: 05/07/2021 DOSAGE EXCLUDED ON NATIONAL DRUG CLASS DRUG NAME GENERIC NAME FORM PERFORMANCE FORMULARY ANEMIA ARANESP SOLN DARBEPOETIN ALFA SOLN INJ ANEMIA ARANESP SOSY DARBEPOETIN ALFA SOLN PREFILLED SYRINGE ANEMIA EPOGEN SOLN EPOETIN ALFA INJ X ANEMIA PROCRIT SOLN EPOETIN ALFA INJ X ANEMIA REBLOZYL SOLR LUSPATERCEPT-AAMT FOR SUBCUTANEOUS INJ ANEMIA RETACRIT SOLN EPOETIN ALFA-EPBX INJ ANTI-GOUT AGENT KRYSTEXXA SOLN PEGLOTICASE INJ (FOR IV INFUSION) ANTI-INFECTIVE PREVYMIS SOLN LETERMOVIR IV SOLN ANTI-INFECTIVE PREVYMIS TABS LETERMOVIR TAB ASTHMA CINQAIR SOLN RESLIZUMAB IV INFUSION SOLN ASTHMA FASENRA SOSY BENRALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE ASTHMA FASENRA PEN SOAJ BENRALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR ASTHMA NUCALA SOAJ MEPOLIZUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR ASTHMA NUCALA SOLR MEPOLIZUMAB FOR INJ ASTHMA NUCALA SOSY MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE ASTHMA XOLAIR SOLR OMALIZUMAB FOR INJ ASTHMA XOLAIR SOSY OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE CARDIOVASCULAR VYNDAMAX CAPS TAFAMIDIS CAP CARDIOVASCULAR VYNDAQEL CAPS TAFAMIDIS MEGLUMINE (CARDIAC) CAP CENTRAL NERVOUS SYSTEM AGENTS AUSTEDO TABS DEUTETRABENAZINE TAB CENTRAL NERVOUS SYSTEM AGENTS ENSPRYNG SOSY SATRALIZUMAB-MWGE SUBCUTANEOUS SOLN PREF SYRINGE CENTRAL NERVOUS SYSTEM AGENTS HETLIOZ CAPS TASIMELTEON CAPSULE CENTRAL NERVOUS SYSTEM AGENTS HETLIOZ LQ SUSP TASIMELTEON ORAL SUSP CHEMOTHERAPY PROTECTANT AMIFOSTINE SOLR AMIFOSTINE CRYSTALLINE FOR INJ CHEMOTHERAPY PROTECTANT ELITEK
  • Phase Ib Study of the Combination of Pexidartinib (PLX3397), a CSF-1R Inhibitor, and Paclitaxel in Patients with Advanced Solid

    Phase Ib Study of the Combination of Pexidartinib (PLX3397), a CSF-1R Inhibitor, and Paclitaxel in Patients with Advanced Solid

    TAM0010.1177/1758835919854238Therapeutic Advances in Medical OncologyR Wesolowski, N Sharma 854238research-article20192019 Therapeutic Advances in Medical Oncology Original Research Ther Adv Med Oncol Phase Ib study of the combination of 2019, Vol. 11: 1 –13 DOI:https://doi.org/10.1177/1758835919854238 10.1177/ pexidartinib (PLX3397), a CSF-1R inhibitor, 1758835919854238https://doi.org/10.1177/1758835919854238 © The Author(s), 2019. Article reuse guidelines: and paclitaxel in patients with advanced sagepub.com/journals- solid tumors permissions Robert Wesolowski, Neelesh Sharma, Laura Reebel, Mary Beth Rodal, Alexandra Peck, Brian L. West, Adhirai Marimuthu, Paul Severson, David A. Karlin, Afshin Dowlati, Mai H. Le, Lisa M. Coussens and Hope S. Rugo Abstract Purpose: To evaluate the safety, recommended phase II dose (RP2D) and efficacy of pexidartinib, a colony stimulating factor receptor 1 (CSF-1R) inhibitor, in combination with weekly paclitaxel in patients with advanced solid tumors. Patients and Methods: In part 1 of this phase Ib study, 24 patients with advanced solid tumors received escalating doses of pexidartinib with weekly paclitaxel (80 mg/m2). Pexidartinib was administered at 600 mg/day in cohort 1. For subsequent cohorts, the dose was increased by ⩽50% using a standard 3+3 design. In part 2, 30 patients with metastatic solid tumors were enrolled to examine safety, tolerability and efficacy of the RP2D. Pharmacokinetics and biomarkers were also assessed. Results: A total of 51 patients reported ≥1 adverse event(s) (AEs) that were at least possibly related to either study drug. Grade 3–4 AEs, including anemia (26%), neutropenia (22%), lymphopenia (19%), fatigue (15%), and hypertension (11%), were Correspondence to: Robert Wesolowski recorded in 38 patients (70%).